Relevant disclosures attached
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fortis Healthcare's Board approved FY2026 audited consolidated financial results with a clean (unmodified) audit opinion from B S R & Co. LLP. Consolidated revenue grew 17.3% year-on-year to ₹912,784 lakhs, while net profit surged 31.5% to ₹106,419 lakhs. EBITDA margin expanded to 23.11% from 20.61% in FY2025, indicating improved operational efficiency. The Board recommended a final dividend of ₹1 per equity share (10% on ₹10 face value) for FY2025-26, subject to shareholder approval. However, the auditors included an Emphasis of Matter drawing attention to an ongoing SFIO investigation regarding alleged improper transactions and non-compliances relating to the period prior to 2018 takeover, and a Supreme Court order for forensic audit of RHT Health Trust transactions. The company has also appointed M/s Jitender, Navneet & Co. as Cost Auditor for FY2026-27.
Strong financial performance with 31.5% PAT growth and margin expansion is positive for shareholders. However, the unresolved regulatory investigations (SFIO and Supreme Court-ordered forensic audit) related to historical promoter misconduct remain a lingering concern that could impact investor sentiment.